Biopharmaceutical company registered in the Cayman Islands with offices in Dublin and research and business operations at South San Francisco, spun out of Theravance Inc in 2014 and listed in New York. Develops and sells medicines for serious illness, with Yupelri, an inhaled long acting muscarinic antagonist for chronic obstructive pulmonary disease marketed with a partner, and works on ampreloxetine for neurogenic orthostatic hypotension, running its own discovery chemistry, respiratory and neurology research and clinical development.
Aucun commentaire disponible.
Laissez votre note & commentaire